Document is current
Any future updates will be listed below
-
Authors
Alayoubi, Myra https://orcid.org/0000-0003-0225-1316
Henry, Brittany A. https://orcid.org/0000-0003-0760-0888
Cahill, Catherine M. https://orcid.org/0000-0001-6936-5524
Cooper, Ziva D. https://orcid.org/0000-0001-8001-2332
-
Funding
Funding for this research was provided by:
Intramural Research Program, National Institute on Drug Abuse (DA047296, DA047296S1, DA057252)
- License Information
-
More Information
Article History
Accepted: 12 September 2024
First Online: 10 October 2024
Declarations
:
: Outside of this work, ZDC reports receiving study drug from Canopy Growth Corp and True Terpenes, and study-related materials from Storz & Bickel. She served as a scientific consultant for Canopy Growth Corporation in 2021 and on the scientific advisory board for FSD Pharma in 2020. ZDC’s research is funded by grants from the National Institute on Drug Abuse, National Center for Complementary and Integrative Health, California Department of Cannabis Control, Center for Medicinal Cannabis Research, and the California Highway Patrol.
: The authors declare that they have no competing interests or disclosures with this publication.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MA: Draft preparation, writing, and review; BAH Draft preparation and writing; CMC reviewing and editing of final submission; ZDC: reviewing, editing, and preparation of final submission.
: All authors have read and approved the final submitted manuscript and agree to be accountable for the work.
